Featured Article
A study found that AI detects prostate cancer more accurately and with fewer false positives than radiologists.
Precision Oncology Today
Magazine
Precision Medicine for Obesity: Targeting a Multifactorial Condition
A report published in 2023, estimates that over 40% of adults in the U.S. have obesity, defined as a body mass index (BMI) of...
New Frontiers in CDx Development
Where is the field of CDx development headed? Today, machine learning and artificial intelligence (AI) are beginning to make an impact on pharma-diagnostic co-development.
Trending on Inside Precision Medicine
Global Research Program Launched to Deploy Blood Biomarker Testing of Alzheimer’s Disease
The Davos Alzheimer’s Collaborative (DAC) announced that it will collaborate with health systems in Germany, the U.K., Japan, the U.S., and the Netherlands to leverage blood biomarkers and confirmatory diagnostic testing to for early identification of Alzheimer’s disease.
Anti-Malarial Compound Shows Promise for Treating Polycystic Ovary Syndrome
Research shows artemisinin, used in anti-malarial drugs, can treat symptoms of polycystic ovary syndrome such as high testosterone levels.
AI-Powered Liquid Biopsy Delivers Ultrasensitive Cancer Detection
An AI-powered test dubbed MRD-EDGE, detected five patients who had a colorectal-cancer recurrence, without any false negatives. MRD-EDGE, may improve cancer care with very early detection of recurrence and close monitoring of tumor response during therapy.
